Eisai Contracts for Land Use for the Establishment of a Pharmaceutical Production Site in Suzhou, China
November 26, 1996 -- Eisai Co., Ltd. of Tokyo (President and CEO: Haruo Naito) announced today that Eisai (Suzhou) Pharmaceutical Co., Ltd. (President: Yusaku Kobayashi), an Eisai affiliate, has contracted for the use of land for the establishment of a pharmaceutical production facility with China-Singapore Suzhou Industrial Park Development Co., Ltd.
Eisai (Suzhou) Pharmaceutical Co., Ltd. will build a 25,000 square meter facility at the China-Singapore Suzhou Industrial Park in Suzhou, Jiangsu province, China. Eisai (Suzhou) Pharmaceutical Co., Ltd. plans to invest US$5 million in the project. The facility is expected to employ approximately 60 when it reaches full commercial operations. Construction of the facility is due to begin in the spring of 1997, with completion planned for 1998. The plant is scheduled to be operational in 2000.
With the facility's completion, Eisai (Suzhou) Pharmaceutical Co., Ltd. will ensure a stable supply for the Chinese pharmaceutical market, which is expected to expand in the future. Eisai (Suzhou) Pharmaceutical Co., Ltd. plans to produce Neuquinon, a metabolic cardiotonic, and other pharmaceutical products which will be submitted for approval in China.
Eisai (Suzhou) Pharmaceutical Co., Ltd., established in March 28, 1996, is a pharmaceutical manufacturing company 100% owned by Eisai Asia Regional Services Pte. Ltd. located in the China-Singapore Suzhou Industrial Park.
Eisai Co., Ltd. is a research-based human health care company which discovers, develops and markets products in more than 30 countries. Through its global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care systems. The company reported sales of over $2.5 billion in fiscal year 1995 with approximately 14 percent of sales spent for research and development.